Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?

J Natl Cancer Inst. 2004 Aug 4;96(15):1117-9. doi: 10.1093/jnci/djh244.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Enzyme Inhibitors / therapeutic use
  • ErbB Receptors / drug effects
  • ErbB Receptors / metabolism*
  • Gefitinib
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Mitogen-Activated Protein Kinase Kinases / drug effects
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Predictive Value of Tests
  • Prognosis
  • Protein Serine-Threonine Kinases / drug effects
  • Protein Serine-Threonine Kinases / metabolism*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Protein-Tyrosine Kinases / metabolism
  • Proto-Oncogene Proteins / drug effects
  • Proto-Oncogene Proteins / metabolism*
  • Proto-Oncogene Proteins c-akt
  • Quinazolines / pharmacology
  • Quinazolines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Proto-Oncogene Proteins
  • Quinazolines
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • AKT1 protein, human
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Mitogen-Activated Protein Kinase Kinases
  • Gefitinib